{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:50:10Z","timestamp":1779897010281,"version":"3.53.1"},"reference-count":56,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health\/National Cancer Institute","award":["P30CA069533"],"award-info":[{"award-number":["P30CA069533"]}]},{"name":"National Institutes of Health\/National Cancer Institute","award":["CBTOP-2023-007"],"award-info":[{"award-number":["CBTOP-2023-007"]}]},{"DOI":"10.13039\/100018071","name":"OHSU Knight Cancer Institute","doi-asserted-by":"publisher","award":["P30CA069533"],"award-info":[{"award-number":["P30CA069533"]}],"id":[{"id":"10.13039\/100018071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018071","name":"OHSU Knight Cancer Institute","doi-asserted-by":"publisher","award":["CBTOP-2023-007"],"award-info":[{"award-number":["CBTOP-2023-007"]}],"id":[{"id":"10.13039\/100018071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Existing clinical biomarkers do not reliably predict treatment response or disease progression in patients with advanced intrahepatic cholangiocarcinoma (ICC). Circulating neoplastic-immune hybrid cells (CHCs) have great promise as a blood-based biomarker for patients with advanced ICC. Peripheral blood specimens were longitudinally collected from patients with advanced ICC enrolled in the HELIX-1 phase II clinical trial (NCT04251715). CHCs were identified by co-expression of pan-cytokeratin (CK) and CD45, and levels were correlated to patient clinical disease course. Unsupervised machine learning was then performed to extract their morphological features to compare them across disease courses. Five patients were included in this study, with a median of nine specimens collected per patient. A median of 13.5 CHCs per 50,000 peripheral blood mononuclear cells were identified at baseline, and levels decreased to zero following the initiation of treatment in all patients. Counts remained undetectable in three patients who demonstrated end-of-trial clinical treatment response and conversely increased in two patients with evidence of therapeutic resistance. In the post-trial surveillance period, interval counts increased prior to or at the time of clinical progression in three patients and remain undetectable in one patient with continued long-term disease stability. Using our machine learning platform, treatment-resistant CHCs exhibited upregulation of CK and downregulation of CD45 relative to treatment-responsive CHCs. CHCs represent a promising blood-based biomarker to supplement traditional radiographic and biochemical measures.<\/jats:p>","DOI":"10.3390\/ijms25179198","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T05:16:24Z","timestamp":1724649384000},"page":"9198","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Exploratory Analyses of Circulating Neoplastic-Immune Hybrid Cells as Prognostic Biomarkers in Advanced Intrahepatic Cholangiocarcinoma"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3672-5735","authenticated-orcid":false,"given":"Ranish K.","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-1681","authenticated-orcid":false,"given":"Michael S.","family":"Parappilly","sequence":"additional","affiliation":[{"name":"Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University (OHSU), Portland, OR 97201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett S.","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7690-1934","authenticated-orcid":false,"given":"Robert T.","family":"Heussner","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Oregon Health & Science University (OHSU), Portland, OR 97201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Fung","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8764-1959","authenticated-orcid":false,"given":"Young Hwan","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Oregon Health & Science University (OHSU), Portland, OR 97201, USA"},{"name":"Knight Cancer Institute, Oregon Health & Science University (OHSU), Portland, OR 97201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6241-4896","authenticated-orcid":false,"given":"Adel","family":"Kardosh","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Oregon Health & Science University (OHSU), Portland, OR 97201, USA"},{"name":"Department of Medicine, Division of Medical Oncology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Lopez","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Oregon Health & Science University (OHSU), Portland, OR 97201, USA"},{"name":"Department of Medicine, Division of Medical Oncology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1631-9855","authenticated-orcid":false,"given":"Skye C.","family":"Mayo","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA"},{"name":"Knight Cancer Institute, Oregon Health & Science University (OHSU), Portland, OR 97201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-279X","authenticated-orcid":false,"given":"Melissa H.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University (OHSU), Portland, OR 97201, USA"},{"name":"Knight Cancer Institute, Oregon Health & Science University (OHSU), Portland, OR 97201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/1477-3163.151940","article-title":"Cancer review: Cholangiocarcinoma","volume":"14","author":"Ghouri","year":"2015","journal-title":"J. Carcinog."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis of two randomised trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","article-title":"Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection","volume":"248","author":"Endo","year":"2008","journal-title":"Ann. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","article-title":"Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial","volume":"6","author":"Cercek","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"De, B., Abu-Gheida, I., Patel, A., Ng, S.S.W., Zaid, M., Thunshelle, C.P., Elganainy, D., Corrigan, K.L., Rooney, M.K., and Javle, M. (2021). Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J. Pers. Med., 11.","DOI":"10.3390\/jpm11121270"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial","volume":"6","author":"Edeline","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/ajt.16906","article-title":"Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma","volume":"22","author":"McMillan","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.surg.2023.04.009","article-title":"Role of genomics in intrahepatic cholangiocarcinoma for liver-directed therapy","volume":"174","author":"Patel","year":"2023","journal-title":"Surgery"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1155\/2013\/196412","article-title":"Serum markers of intrahepatic cholangiocarcinoma","volume":"34","author":"Malaguarnera","year":"2013","journal-title":"Dis. Markers"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s13277-011-0297-8","article-title":"CA 19-9 in pancreatic cancer: Retrospective evaluation of patients with suspicion of pancreatic cancer","volume":"33","author":"Molina","year":"2012","journal-title":"Tumour Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.3748\/wjg.15.5976","article-title":"Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma","volume":"15","author":"Shen","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Azizian, A., R\u00fchlmann, F., Krause, T., Bernhardt, M., Jo, P., K\u00f6nig, A., Klei\u00df, M., Leha, A., Ghadimi, M., and Gaedcke, J. (2020). CA 19-9 for detecting recurrence of pancreatic cancer. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-57930-x"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.21873\/anticanres.12931","article-title":"Relationship Between CA 19.9 and the Lewis Phenotype: Options to Improve Diagnostic Efficiency","volume":"38","author":"Santos","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1007\/s11605-021-04911-8","article-title":"Detection of Tumor Multifocality in Resectable Intrahepatic Cholangiocarcinoma: Defining the Optimal Pre-operative Imaging Modality","volume":"25","author":"Sutton","year":"2021","journal-title":"J. Gastrointest. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1002\/cncr.34854","article-title":"The association of carbohydrate antigen 19-9 response with radiologic response and survival in intrahepatic cholangiocarcinoma: A prospective cohort study","volume":"129","author":"Cai","year":"2023","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1126\/science.1244270","article-title":"Cancer. Fusion for moving","volume":"342","author":"Clawson","year":"2013","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Clawson, G.A., Kimchi, E., Patrick, S.D., Xin, P., Harouaka, R., Zheng, S., Berg, A., Schell, T., Staveley-O\u2019Carroll, K.F., and Neves, R.I. (2012). Circulating tumor cells in melanoma patients. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0041052"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Dietz, M.S., Sutton, T.L., Walker, B.S., Gast, C.E., Zarour, L., Sengupta, S.K., Swain, J.R., Eng, J., Parappilly, M., and Limbach, K. (2021). Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-93053-7"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"eaat7828","DOI":"10.1126\/sciadv.aat7828","article-title":"Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival","volume":"4","author":"Gast","year":"2018","journal-title":"Sci. Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hed.26692","article-title":"Circulating hybrid cells predict presence of occult nodal metastases in oral cavity carcinoma","volume":"43","author":"Henn","year":"2021","journal-title":"Head Neck"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1097\/PAS.0b013e3182322cf7","article-title":"\u201cStealth\u201d melanoma cells in histology-negative sentinel lymph nodes","volume":"35","author":"Itakura","year":"2011","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Lazova, R., Laberge, G.S., Duvall, E., Spoelstra, N., Klump, V., Sznol, M., Cooper, D., Spritz, R.A., Chang, J.T., and Pawelek, J.M. (2013). A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human Cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066731"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Parappilly, M.S., Chin, Y., Whalen, R.M., Anderson, A.N., Robinson, T.S., Strgar, L., Sutton, T.L., Conley, P., Klocke, C., and Gibbs, S.L. (2022). Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal Melanoma. Cancers, 14.","DOI":"10.3390\/cancers14194617"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/978-3-031-37936-9_21","article-title":"The Hallmarks of Circulating Hybrid Cells","volume":"71","author":"Patel","year":"2024","journal-title":"Results Probl. Cell Differ."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1245\/s10434-021-10379-2","article-title":"Circulating Hybrid Cells: A Novel Liquid Biomarker of Treatment Response in Gastrointestinal Cancers","volume":"28","author":"Walker","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ali, A.M., and Raza, A. (2024). scRNAseq and High-Throughput Spatial Analysis of Tumor and Normal Microenvironment in Solid Tumors Reveal a Possible Origin of Circulating Tumor Hybrid Cells. Cancers, 16.","DOI":"10.3390\/cancers16071444"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.1038\/s41467-023-42303-5","article-title":"Phagocytosis-initiated tumor hybrid cells acquire a c-Myc-mediated quasi-polarization state for immunoevasion and distant dissemination","volume":"14","author":"Chou","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Fr\u00fcndt, T., von Felden, J., Krause, J., Heumann, A., Li, J., Riethdorf, S., Pantel, K., Huber, S., Lohse, A.W., and Wege, H. (2022). Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.941660"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Sutton, T.L., Patel, R.K., Anderson, A.N., Bowden, S.G., Whalen, R., Giske, N.R., and Wong, M.H. (2022). Circulating Cells with Macrophage-like Characteristics in Cancer: The Importance of Circulating Neoplastic-Immune Hybrid Cells in Cancer. Cancers, 14.","DOI":"10.3390\/cancers14163871"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cyto.a.24826","article-title":"Quantitative image analysis pipeline for detecting circulating hybrid cells in immunofluorescence images with human-level accuracy","volume":"105","author":"Heussner","year":"2024","journal-title":"Cytom. Part A"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jamcollsurg.2013.05.021","article-title":"Intrahepatic cholangiocarcinoma: Management options and emerging therapies","volume":"217","author":"Dodson","year":"2013","journal-title":"J. Am. Coll. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1245\/s10434-014-4223-3","article-title":"Is Hepatic Resection for Large or Multifocal Intrahepatic Cholangiocarcinoma Justified? Results from a Multi-Institutional Collaboration","volume":"22","author":"Spolverato","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e1901875","DOI":"10.1002\/adhm.201901875","article-title":"Exploring Circulating Tumor Cells in Cholangiocarcinoma Using a Novel Glycosaminoglycan Probe on a Microfluidic Platform","volume":"9","author":"Gopinathan","year":"2020","journal-title":"Adv. Healthc. Mater."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Malkawi, W., Lutfi, A., Afghan, M.K., Shah, L.M., Costandy, L., Ramirez, A.B., George, T.C., Toor, F., Salem, A.K., and Kasi, P.M. (2023). Circulating tumour cell enumeration, biomarker analyses, and kinetics in patients with colorectal cancer and other GI malignancies. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1305181"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Manjunath, Y., Porciani, D., Mitchem, J.B., Suvilesh, K.N., Avella, D.M., Kimchi, E.T., Staveley-O\u2019Carroll, K.F., Burke, D.H., Li, G., and Kaifi, J.T. (2020). Tumor-Cell-Macrophage Fusion Cells as Liquid Biomarkers and Tumor Enhancers in Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051872"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10544-014-9856-2","article-title":"Microfluidic platform for negative enrichment of circulating tumor cells","volume":"16","author":"Sajay","year":"2014","journal-title":"Biomed. Microdevices"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nature06385","article-title":"Isolation of rare circulating tumour cells in cancer patients by microchip technology","volume":"450","author":"Nagrath","year":"2007","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e2000171","DOI":"10.1002\/smll.202000171","article-title":"Microfluidic-Based Approaches in Targeted Cell\/Particle Separation Based on Physical Properties: Fundamentals and Applications","volume":"16","author":"Nasiri","year":"2020","journal-title":"Small"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/ajcp\/aqac040","article-title":"Clinical Validation of a Circulating Tumor Cell Assay Using Density Centrifugation and Automated Immunofluorescence Microscopy","volume":"158","author":"Sabath","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"29569","DOI":"10.1021\/acsami.9b09655","article-title":"Antibody-Functional Microsphere-Integrated Filter Chip with Inertial Microflow for Size-Immune-Capturing and Digital Detection of Circulating Tumor Cells","volume":"11","author":"Su","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1073\/pnas.0813188106","article-title":"Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device","volume":"106","author":"Talasaz","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kim, K.H., Yi, H.S., Lee, H., Bae, G.E., and Yeo, M.K. (2023). Targeting the Sequences of Circulating Tumor DNA of Cholangiocarcinomas and Its Applications and Limitations in Clinical Practice. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087512"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1158\/1078-0432.CCR-22-3626","article-title":"The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal Cancers","volume":"29","author":"Lee","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1245\/s10434-023-13126-x","article-title":"Optimizing Circulating Tumour DNA Use in the Perioperative Setting for Intrahepatic Cholangiocarcinoma: Diagnosis, Screening, Minimal Residual Disease Detection and Treatment Response Monitoring","volume":"30","author":"Choi","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/PO.20.00178","article-title":"Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations","volume":"5","author":"Varghese","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Winter, H., Kaisaki, P.J., Harvey, J., Giacopuzzi, E., Ferla, M.S.P., Pentony, M.M., Knight, S.J.L., Sharma, R.A., Taylor, J.C., and McCullagh, J.S.O. (2019). Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma. Cancers, 11.","DOI":"10.3390\/cancers11121895"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e154941","DOI":"10.1172\/JCI154941","article-title":"Circulating tumor DNA: Current challenges for clinical utility","volume":"132","author":"Dang","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41587-021-01094-0","article-title":"Whole-cell segmentation of tissue images with human-level performance using large-scale data annotation and deep learning","volume":"40","author":"Greenwald","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_53","first-page":"1","article-title":"beta-vae: Learning basic visual concepts with a constrained variational framework","volume":"3","author":"Higgins","year":"2017","journal-title":"ICLR (Poster)"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Fu, H., Li, C., Liu, X., Gao, J., Celikyilmaz, A., and Carin, L. (2019). Cyclical Annealing Schedule: A Simple Approach to Mitigating. arXiv.","DOI":"10.18653\/v1\/N19-1021"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"McInnes, L., Healy, J., and Melville, J. (2018). Umap: Uniform manifold approximation and projection for dimension reduction. arXiv.","DOI":"10.21105\/joss.00861"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9198\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:42:49Z","timestamp":1760110969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":56,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ijms25179198"],"URL":"https:\/\/doi.org\/10.3390\/ijms25179198","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,24]]}}}